ADIA Nutrition Submits Patent-Pending Autism Protocol for IRB Review, Advancing Stem Cell Therapy Study
核心洞察
ADIA Nutrition (搜索) has submitted its complete patent-pending regenerative protocol for pediatric Autism Spectrum Disorder (搜索) to an independent Institutional Review Board for full review and potential oversight acceptance.
The protocol combines antioxidants (搜索) and stem cells (搜索) for treating children with ASD (搜索) and represents the company's first potential IRB-approved human study in this therapeutic area.
IRB acceptance would authorize immediate study launch and could accelerate access to additional IRBs, potentially generating significant clinical data for families affected by autism spectrum disorders.
ADIA Nutrition (搜索), Inc. (OTCQB: ADIA) has submitted its complete patent-pending regenerative protocol for pediatric Autism Spectrum Disorder (搜索) (ASD (搜索)) to an independent Institutional Review Board (IRB) for comprehensive review and potential oversight acceptance. The submission follows the IRB's initial acceptance of the company's draft protocol and formal invitation to submit a final version.
The protocol represents a novel therapeutic approach combining antioxidants (搜索) and stem cells (搜索) for treating children with ASD (搜索). According to the company, the submission includes detailed methodology, rigorous safety measures, dosing regimen, and clinical endpoints, all now under expert evaluation by the IRB.
Clinical Development Milestone
This submission marks a pivotal milestone for ADIA Nutrition (搜索), as IRB acceptance would immediately authorize the company's first-ever IRB-approved human study using this combination therapy in pediatric ASD (搜索) patients. The protocol remains confidential while intellectual property and clinical pathways advance in parallel.
"We just pressed the button on something that could be truly game-changing," said Larry Powalisz, CEO of ADIA Nutrition (搜索). "The IRB now has everything they need to green-light our work. Acceptance would open the floodgates to many more IRBs and fast-track credible, life-changing data for families, and explosive value for shareholders."
Regenerative Medicine Platform
ADIA Nutrition (搜索) operates through multiple divisions, including AdiaLabs LLC (搜索), which specializes in stem cell and regenerative products such as AdiaVita (搜索) and AdiaLink (搜索). The company's Adia Med (搜索) clinics offer specialized regenerative treatments including stem cell therapies, platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT).
The Winter Park, Florida-based company generates revenue through service fees, product sales, equity stakes, and insurance billing for healthcare treatments. The company is actively expanding its network of Adia Med (搜索) clinics nationwide, focusing on orthopedic, pain management, and wound repair services.
Strategic Partnerships and Expansion
ADIA Nutrition (搜索) is actively seeking strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med (搜索) name or integrating the company's regenerative therapies into their practice. These partnerships align with the company's mission to expand access to advanced stem cell solutions.
The company has indicated that shareholders will receive prompt updates throughout the IRB review process, with the next announcement expected to be significantly larger upon IRB determination. The timeline for IRB decision remains unspecified, though the company suggests the review process is actively underway.